ArticleJournal of diabetes investigation2026
Investigation and future trend prediction of disease burden of chronic kidney disease due to diabetes mellitus type 2 globally and in China from 1990 to 2021.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo analyze the disease burden of chronic kidney disease due to diabetes mellitus type 2 (CKD due to diabetes mellitus type 2) in China and the global population from 1990 to 2021, and to predict the future trend of the population.
methodsJoinpoint regression quantifies trends by the average annual percentage change (AAPC). Decomposition analysis assessed the contribution of aging, population growth, and epidemiological transitions to changes in the disease burden. The Bayesian model predicts the number of cases and deaths in 2022-2031.
resultsFrom 1990 to 2021, the global and Chinese age-standardized incidence rates (ASIRs) showed an upward trend, of which the global AAPC was 1.928% (95% CI = 1.908-1.948%); global and Chinese age-standardized mortality rates (ASMRs) are on the rise. In the decomposition analysis, population growth was the main driving force for the increase of global and Chinese cases and deaths, accounting for 60.14, 53.99, 56.64, and 72.82% of the change, respectively. 87.17% of the global age-standardized DALY rate was attributed to hyperglycemia. High BMI has become a major risk factor in China. It is expected that by 2031, the number of ASIR and deaths of CKD worldwide will continue to rise.
conclusionsThe CKD due to diabetes mellitus type 2 burden remains severe worldwide and in China. Strengthened public health policies and clinical prevention strategies are urgently needed to mitigate this burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.